Metabolic syndrome laboratory findings: Difference between revisions
| Line 18: | Line 18: | ||
* [[Fibrinogen]] | * [[Fibrinogen]] | ||
* [[Homocysteine]] | * [[Homocysteine]] | ||
Studies have shown that elevated levels of these proinflammatory and prothrombotic biomarkers are associated with an increased risk for [[coronary artery disease]] ([[CAD]]) and [[type II diabetes]]. Hence measurement of these markers should be considered in the setting of CAD risk assessment. | |||
==References== | ==References== | ||
Revision as of 14:22, 30 April 2013
|
Metabolic syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Metabolic syndrome laboratory findings On the Web |
|
American Roentgen Ray Society Images of Metabolic syndrome laboratory findings |
|
Risk calculators and risk factors for Metabolic syndrome laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
The diagnosis of metabolic syndrome is mostly based on physical examination and lab tests. The diagnostic criteria of different international societies also involves consideration of lab tests like lipid profile and fasting blood glucose.
Laboratory Findings
- Blood glucose (fasting, post-prandial) and HbA1C to assess for diabetes
- Renal function tests like serum uric acid and urinary microalbumin to look for renal dysfunction. Hyperuricemia has been frequently shown to be associated with metabolic syndrome.
- Lipid profile - hypertriglyceridemia or low HDL levels to assess dyslipidemia.
- Thyroid function tests - as increased thyroid stimulating hormone (TSH) has been linked to a higher prevalence of metabolic syndrome
- Liver function tests
Metabolic syndrome is a proinflammatory and prothrombotic state. Additional biomarkers that are worth measuring while evaluating metabolic syndrome include:
- ApoB
- High sensitivity CRP
- Fibrinogen
- Homocysteine
Studies have shown that elevated levels of these proinflammatory and prothrombotic biomarkers are associated with an increased risk for coronary artery disease (CAD) and type II diabetes. Hence measurement of these markers should be considered in the setting of CAD risk assessment.